Search research articles
Contact Us
Filters
Showing results (41-50 of 75) with videos related to
Page
of 8
Sort By:
Biochimica Et Biophysica Acta. Molecular Basis of Disease
|
March 7, 2020
Decoding molecular interplay between RUNX1 and FOXO3a underlying the pulsatile IGF1R expression during acquirement of chemoresistance
Ajit C Dhadve, Kishore Hari, Bharat Rekhi, et al.
Biomarkers in Medicine
|
May 30, 2019
IGF1R predicts better survival in high-grade serous epithelial ovarian cancer patients and correlates with hCtr1 levels
Abhilash Deo, Smrita Chaudhury, Sadhana Kannan, et al.
Plos Medicine
|
August 22, 2008
Cancer screening: a mathematical model relating secreted blood biomarker levels to tumor sizes
Amelie M Lutz, Juergen K Willmann, Frank V Cochran, et al.
Cancer Letters
|
August 27, 2014
IGF-1R inhibition potentiates cytotoxic effects of chemotherapeutic agents in early stages of chemoresistant ovarian cancer cells
Ram K Singh, Snehal M Gaikwad, Ankit Jinager, et al.
Journal of Biomedical Optics
|
January 1, 2008
Multimodality imaging of T-cell hybridoma trafficking in collagen-induced arthritic mice: image-based estimation of the number of cells accumulating in mouse paws
Shahriar S Yaghoubi, Remi J Creusot, Pritha Ray, et al.
Plos One
|
February 9, 2013
Non-invasive imaging of phosphoinositide-3-kinase-catalytic-subunit-alpha (PIK3CA) promoter modulation in small animal models
Snehal M Gaikwad, Lata Gunjal, Anitha R Junutula, et al.
Diagnostics (Basel, Switzerland)
|
February 25, 2023
Through the Looking Glass: Updated Insights on Ovarian Cancer Diagnostics
Sourav Chakraborty, Priti S Shenoy, Megha Mehrotra, et al.
Journal of Cancer Research and Therapeutics
|
October 15, 2014
A novel series of di-fluorinated propanedione derivatives synergistically augment paclitaxel mediated caspase 3 activation in ovarian cancer cells
Jyothi Nagraj, Subhoshree Chatterjee, Tanushree Pal, et al.
Research Square
|
April 1, 2025
Hotspot mutations in HER2 interfaces destabilize structure, causing breast cancer treatment failure
Abhijit De, Pranay Dey, Aniketh Bishnu, et al.
Oncogene
|
December 14, 2025
Hotspot mutations in HER2 interfaces destabilize structure, causing breast cancer treatment failure
Pranay Dey, Aniketh Bishnu, Janvi Patel, et al.
Page
of 8
Search research articles
Search
Showing results (41-50 of 75) with videos related to
Sort By:
Page
of 8
Biochimica Et Biophysica Acta. Molecular Basis of Disease
|
March 7, 2020
Decoding molecular interplay between RUNX1 and FOXO3a underlying the pulsatile IGF1R expression during acquirement of chemoresistance
Ajit C Dhadve, Kishore Hari, Bharat Rekhi, et al.
Biomarkers in Medicine
|
May 30, 2019
IGF1R predicts better survival in high-grade serous epithelial ovarian cancer patients and correlates with hCtr1 levels
Abhilash Deo, Smrita Chaudhury, Sadhana Kannan, et al.
Plos Medicine
|
August 22, 2008
Cancer screening: a mathematical model relating secreted blood biomarker levels to tumor sizes
Amelie M Lutz, Juergen K Willmann, Frank V Cochran, et al.
Cancer Letters
|
August 27, 2014
IGF-1R inhibition potentiates cytotoxic effects of chemotherapeutic agents in early stages of chemoresistant ovarian cancer cells
Ram K Singh, Snehal M Gaikwad, Ankit Jinager, et al.
Journal of Biomedical Optics
|
January 1, 2008
Multimodality imaging of T-cell hybridoma trafficking in collagen-induced arthritic mice: image-based estimation of the number of cells accumulating in mouse paws
Shahriar S Yaghoubi, Remi J Creusot, Pritha Ray, et al.
Plos One
|
February 9, 2013
Non-invasive imaging of phosphoinositide-3-kinase-catalytic-subunit-alpha (PIK3CA) promoter modulation in small animal models
Snehal M Gaikwad, Lata Gunjal, Anitha R Junutula, et al.
Diagnostics (Basel, Switzerland)
|
February 25, 2023
Through the Looking Glass: Updated Insights on Ovarian Cancer Diagnostics
Sourav Chakraborty, Priti S Shenoy, Megha Mehrotra, et al.
Journal of Cancer Research and Therapeutics
|
October 15, 2014
A novel series of di-fluorinated propanedione derivatives synergistically augment paclitaxel mediated caspase 3 activation in ovarian cancer cells
Jyothi Nagraj, Subhoshree Chatterjee, Tanushree Pal, et al.
Research Square
|
April 1, 2025
Hotspot mutations in HER2 interfaces destabilize structure, causing breast cancer treatment failure
Abhijit De, Pranay Dey, Aniketh Bishnu, et al.
Oncogene
|
December 14, 2025
Hotspot mutations in HER2 interfaces destabilize structure, causing breast cancer treatment failure
Pranay Dey, Aniketh Bishnu, Janvi Patel, et al.
Page
of 8